loading
Range Cancer Therapeutics Etf stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$9.02
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
Value
$0.00
$0.00
1-Week Range:
Value
$0.00
$9.41
52-Week Range:
Value
$0.00
$16.27

Range Cancer Therapeutics Etf Stock (CNCR) Company Profile

Name
Name
Range Cancer Therapeutics Etf
Name
Phone
-
Name
Address
-
Name
Employee
0
Name
Twitter
@LoncarFunds
Name
Next Earnings Date
Name
Latest SEC Filings
Name
CNCR's Discussions on Twitter

Compare CNCR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Exchange Traded Fund icon
CNCR
Range Cancer Therapeutics Etf
0.00 0 0 0 0 0.00
Exchange Traded Fund icon
VTI
Vanguard Total Stock Market Etf
289.88 417.53B 0 0 0 0.00
Exchange Traded Fund icon
SPY
Spdr S P 500 Etf Trust
589.39 372.57B 0 0 0 0.00
Exchange Traded Fund icon
IVV
Ishares Core S P 500 Etf
592.15 253.41B 0 0 0 0.00
Exchange Traded Fund icon
VB
Vanguard Small Cap Etf
228.19 160.59B 0 0 0 0.00
Exchange Traded Fund icon
QQQ
Invesco Qqq Trust Series 1
519.11 124.43B 0 0 0 0.00

Range Cancer Therapeutics Etf Stock (CNCR) Latest News

pulisher
May 30, 2025

Summit stock down after cancer trial data (update) (NASDAQ:SMMT) - Seeking Alpha

May 30, 2025
pulisher
May 29, 2025

Friday's big stock stories: What’s likely to move the market in the next trading session - CNBC

May 29, 2025
pulisher
May 20, 2025

5 Small-cap Biotech ETFs to Watch - Investing News Network

May 20, 2025
pulisher
May 18, 2025

Trend Tracker for (CNCR) - news.stocktradersdaily.com

May 18, 2025
pulisher
May 14, 2025

CIBC Asset Management launches three new actively managed CIBC ETFs, expanding its cash management and fixed income ETF suite - The Globe and Mail

May 14, 2025
pulisher
May 10, 2025

Weekly ETF Industry Recap: U.S., Europe, and Canada HighlightsMay 5-10, 2025 - Trackinsight

May 10, 2025
pulisher
May 08, 2025

Exchange Traded Concepts to Close and Liquidate the Range Cancer Therapeutics ETF - The Joplin Globe

May 08, 2025
pulisher
May 08, 2025

Learn to Evaluate (CNCR) using the Charts - news.stocktradersdaily.com

May 08, 2025
pulisher
Apr 28, 2025

Mythic Therapeutics Presents Preclinical Data Demonstrating Potent Efficacy of MYTX-011 Across a Broad Range of Tumor Xenograft Models Harboring Clinically Relevant Mutations at the American Association for Cancer Research (AACR) Annual Meeting - Yahoo Finance

Apr 28, 2025
pulisher
Apr 23, 2025

Cathie Wood Bets on Nvidia, AMD Despite Chip Curbs and Dumps Microsoft Stock - The Globe and Mail

Apr 23, 2025
pulisher
Apr 22, 2025

Long Term Trading Analysis for (CNCR) - news.stocktradersdaily.com

Apr 22, 2025
pulisher
Apr 21, 2025

7 Best Pharmaceutical Stocks to Buy for Income - US News Money

Apr 21, 2025
pulisher
Apr 08, 2025

From Panic to Positioning: Top ETFs to Watch After Asia’s Tariff Shock - The Globe and Mail

Apr 08, 2025
pulisher
Apr 06, 2025

(CNCR) Investment Report - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Apr 04, 2025

10 Best Health Care Stocks to Buy for 2025 - US News Money

Apr 04, 2025
pulisher
Apr 03, 2025

7 Top Gene-Editing Stocks to Buy | Investing | U.S. News - Money/ US News

Apr 03, 2025
pulisher
Mar 28, 2025

Best Stocks Under $20 Right Now - Benzinga

Mar 28, 2025
pulisher
Mar 27, 2025

Sellas Life Sciences Advances in Cancer Treatment Development - TipRanks

Mar 27, 2025
pulisher
Mar 25, 2025

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - Nasdaq

Mar 25, 2025
pulisher
Mar 20, 2025

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer - Nasdaq

Mar 20, 2025
pulisher
Mar 19, 2025

QQQ ETF News, 3/19/2025 - The Globe and Mail

Mar 19, 2025
pulisher
Mar 16, 2025

(CNCR) Proactive Strategies - Stock Traders Daily

Mar 16, 2025
pulisher
Mar 15, 2025

Nasdaq Correction: Buy This Unstoppable ETF at a Discount - The Globe and Mail

Mar 15, 2025
pulisher
Mar 14, 2025

Buffer ETFs to Consider for Protecting Gains and Limiting Losses - The Globe and Mail

Mar 14, 2025
pulisher
Mar 14, 2025

S&P 500 Index Funds Yield Just 1.3%. Consider Buying These 2 Low-Cost Vanguard ETFs to Generate More Passive Income. - The Globe and Mail

Mar 14, 2025
pulisher
Mar 14, 2025

VOO ETF News, 3/14/2025 - The Globe and Mail

Mar 14, 2025
pulisher
Mar 12, 2025

VOO ETF News, 3/12/2025 - The Globe and Mail

Mar 12, 2025
pulisher
Mar 12, 2025

Is the Fidelity High Dividend ETF the Smartest Investment You Can Make Today? - The Globe and Mail

Mar 12, 2025
pulisher
Mar 11, 2025

Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You? - The Globe and Mail

Mar 11, 2025
pulisher
Mar 11, 2025

These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy? - The Globe and Mail

Mar 11, 2025
pulisher
Mar 11, 2025

SCHD ETF News, 3/11/2025 - The Globe and Mail

Mar 11, 2025
pulisher
Mar 11, 2025

1 No-Brainer Artificial Intelligence (AI) ETF to Buy With $40 During the Nasdaq Sell-Off - The Globe and Mail

Mar 11, 2025
pulisher
Mar 08, 2025

Why You Can Do Better Than the SPDR S&P 500 ETF Trust - The Globe and Mail

Mar 08, 2025
pulisher
Mar 07, 2025

3 Top Cancer Biotechs to Keep An Eye On in 2025 - Yahoo Finance

Mar 07, 2025
pulisher
Mar 06, 2025

Best Biotech Stocks to Buy in 2025 - The Motley Fool

Mar 06, 2025
pulisher
Mar 05, 2025

(CNCR) Investment Analysis - news.stocktradersdaily.com

Mar 05, 2025
pulisher
Mar 03, 2025

7 Best-Performing Biotech ETFs for March 2025 - NerdWallet

Mar 03, 2025
pulisher
Feb 28, 2025

Top ETFs to Invest in Japan - The Globe and Mail

Feb 28, 2025
pulisher
Feb 26, 2025

N2OFF, Inc. Enters Agreement to Acquire MitoCareX Bio Ltd. to Expand Cancer Therapeutics Portfolio - Nasdaq

Feb 26, 2025
pulisher
Feb 25, 2025

Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025 - Investing News Network

Feb 25, 2025
pulisher
Feb 24, 2025

CIBC Asset Management announces CIBC ETF cash distributions for February 2025 - The Globe and Mail

Feb 24, 2025
pulisher
Feb 23, 2025

(CNCR) Trading Signals - Stock Traders Daily

Feb 23, 2025
pulisher
Feb 20, 2025

The Unstoppable Momentum in Oncology M&A - Nasdaq

Feb 20, 2025
pulisher
Feb 18, 2025

2025 Outlook: Healthcare Technology & Innovation - ETF Trends

Feb 18, 2025
pulisher
Feb 14, 2025

This Warren Buffett Index Fund Could Turn $400 Per Month Into $868,200 - The Globe and Mail

Feb 14, 2025
pulisher
Feb 10, 2025

Psychedelic ETF PSIL Is 2025's Best-Performing ETF - etf.com

Feb 10, 2025
pulisher
Feb 07, 2025

TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright - Armenian Reporter

Feb 07, 2025
pulisher
Feb 01, 2025

When (CNCR) Moves Investors should Listen - Stock Traders Daily

Feb 01, 2025
pulisher
Jan 28, 2025

SELLAS Life Sciences Group, Inc. Secures $25 Million in Registered Direct Offering for Cancer Therapeutics Development - Nasdaq

Jan 28, 2025
pulisher
Jan 27, 2025

Reston Hospital Center adds inpatient unit to expand its range of oncology services - Yahoo Finance

Jan 27, 2025
pulisher
Jan 23, 2025

5 US Longevity and Anti-aging Stocks to Watch in 2025 - Investing News Network

Jan 23, 2025

Range Cancer Therapeutics Etf Stock (CNCR) Financials Data

There is no financial data for Range Cancer Therapeutics Etf (CNCR). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
exchange_traded_fund VTV
$171.39
price up icon 0.16%
exchange_traded_fund VUG
$413.14
price down icon 0.09%
exchange_traded_fund IJH
$60.04
price down icon 0.41%
exchange_traded_fund EFA
$88.81
price up icon 0.15%
exchange_traded_fund IWF
$399.43
price down icon 0.09%
exchange_traded_fund QQQ
$519.11
price down icon 0.16%
Cap:     |  Volume (24h):